Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-10-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
监事会关于2022年限制性股票激励计划首次授予第一个归属期归属名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the first vesting period list for a 2022 restricted stock incentive plan. It discusses compliance with company law, securities law, and internal company regulations regarding stock incentives. The content is related to stock incentive plan verification and approval, not a full report or financial statement. It is an announcement related to share-based compensation and internal governance but does not fit categories like Remuneration Information (DEF 14A) which typically detail compensation amounts, nor is it a full governance report. It is a regulatory announcement about stock incentive plan vesting approval, best classified under Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal compliance disclosure.
2023-10-30 Chinese
第四届监事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 19th meeting of the 4th Supervisory Board of the company. It details the meeting's convening, attendance, and voting results on specific agenda items related to stock incentive plans. There is no financial data, no report attached or referenced as being published, and no indication of a full report or presentation. The content is about board-level decisions and approvals, specifically from the supervisory board, which aligns with Board/Management Information filings. The document is short (1441 characters) and is an announcement of meeting resolutions, not a full report or financial statement. Therefore, the appropriate classification is MANG (Board/Management Information).
2023-10-30 Chinese
北京市康达律师事务所关于拓新药业集团股份有限公司2022年限制性股票激励计划授予价格调整、部分已授予尚未归属的限制性股票作废及第一个归属期归属条件成就相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of a company. It discusses the adjustment of the grant price, cancellation of some unvested restricted stocks, and the achievement of the first vesting period conditions. The document references relevant laws and regulations, board and shareholder approvals, and detailed conditions and results of the stock incentive plan. It is not a financial report, earnings release, or management discussion, but a legal opinion on a specific corporate action related to stock incentives. This type of document fits best under Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance matters, not a direct report or announcement of financial results or capital changes.
2023-10-30 Chinese
关于调整2022年限制性股票激励计划授予价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the grant price of a 2022 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and financial advisor opinions related to the stock incentive plan. The document does not contain full financial statements or comprehensive financial performance data, nor is it a transcript, earnings release, or annual/interim report. It is a formal announcement about a specific corporate action related to stock incentives, which fits best under regulatory announcements about capital or financing activities. Given the nature of the content focusing on stock incentive plan adjustments and related approvals, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about the adjustment, not merely a report publication announcement or a brief notice. Therefore, it is not RPA or RNS. Confidence is high due to clear focus on stock incentive plan price adjustment and related corporate approvals.
2023-10-30 Chinese
关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of part of its 2022 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and financial advisor opinions related to the adjustment and cancellation of restricted stock awards. The content focuses on corporate governance and management decisions about stock incentives rather than financial results or earnings. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The document is a formal disclosure about management decisions on stock incentives, which fits best under Board/Management Information (MANG).
2023-10-30 Chinese
关于2022年限制性股票激励计划第一个归属期归属条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the achievement of the first vesting conditions of a 2022 restricted stock incentive plan by a company named 拓新药业集团股份有限公司. It includes specifics about the number of shares vested, the vesting schedule, performance targets, approval procedures, and legal and financial advisor opinions. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is not a call transcript, earnings release, or a general regulatory filing. The content focuses on the vesting and allocation of restricted stock under an equity incentive plan, which is a capital/financing update related to share issuance and stock-based compensation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9398 characters) and detailed content confirm it is a substantive update, not just a brief announcement or certification.
2023-10-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.